ALN-6400

Phase 2

Alnylam Pharmaceuticals, Inc. (ALNY)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q2 '27

ALNYPhase 2$33.2B

ALN-6400 Phase 2 Est. Readout (HMBeacon)

ALN-6400• Hereditary Hemorrhagic Telangiectasia24

Q2 2027~QEstimated

CT.gov

00%

Competitive Landscape

0 competitors in Hereditary Hemorrhagic Telangiectasia

View Full Landscape

Drug Information

Target Indication

Hereditary Hemorrhagic Telangiectasia

Clinical Trial

NCT06659640

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

ALNY

Alnylam Pharmaceuticals, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

NucresiranPhase 3

Transthyretin Amyloidosis With Cardiomyopathy

VutrisiranPhase 3

Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

LumasiranPhase 3

PH1

ZilebesiranPhase 3

Hypertension

patisiran (ALN-TTR02)Phase 3

TTR-mediated Amyloidosis

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts